Sentence examples for have yet progressed from inspiring English sources

Thus far, relatively few selective inhibitors of Chk2 have been described and none have yet progressed into clinical trials.

Several p53-targeting small molecules have demonstrated very promising activity in pre-clinical studies but have yet progressed to the clinical setting.

We did not perform right-heart catheterization in our patients, as the study aim was to detect patterns of early PV in patients who might not have yet progressed to clinical resting pulmonary hypertension, so that an elevated PAP during a resting right heart catheterization might not have been evident, given a normal systolic PAP on echocardiography.

No Kaplan-Maier estimations are available for 6th and 7th line treatment, as only one patient has yet progressed on 6th line therapy (after 8 months), and the only patient receiving a 7th line treatment progressed after 3 months.

Although none of the sites has yet progressed to actual record linkage based on the collected fingerprint templates, the technical feasibility and acceptability of collecting fingerprints in health care facility and household contexts have been confirmed.

The mentioned examples underscore that employing translational research approaches in PTSD biomarker research is a very promising endeavor that should be taken forward since, in contrast to biomarkers for example for internal disorders, no putative biomarker for PTSD or for any other psychiatric disorder except for dementia has yet progressed to the point of practical use [ 24].

Many of them have yet to progress beyond laboratory prototypes.

Even in the extremely young LV species flock, preorbital evolution has been extensive (Figure 4) while other types of cranial anatomical diversification have yet to progress much at all (Figures 3 and 6).

However, these have yet to progress to human clinical trials.

The potential toxicity of pan-FGFR inhibition could therefore be avoided by use of FGFR inhibitory antibodies whose side effects would be limited to those of a single FGFR member, although FGFR1/FGFR2 antibodies have yet to progress beyond preclinical development.

Patients who have not yet progressed to ESRD may have unique barriers to considering LKT, including their lack of awareness of the severity of their kidney disease [ 11] and low perceived susceptibility to kidney disease progression and ESRD [ 12].